• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NanoString Announces Commercial Leadership Transition

    1/9/22 11:35:00 AM ET
    $NSTG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NSTG alert in real time by email

    Chad Brown to Retire Following More than Four Successful Years as SVP, Sales & Marketing

    Genomics and Diagnostics Veteran John D. Gerace Appointed as Chief Commercial Officer

    NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced a commercial leadership transition. Chad Brown, who has served as senior vice president of Sales & Marketing since June 2017, will be shifting into a part-time senior advisor role effective April 1, before fully retiring in March 2023. John D. Gerace has been named to the position of Chief Commercial Officer effective immediately.

    Mr. Brown joined NanoString in July 2017 and initiated a comprehensive portfolio review, and implemented substantial improvements in sales processes, the global expansion of the commercial organization and the successful launch of GeoMx Digital Spatial Profiler.

    "I joined NanoString over four years ago to build a world-class commercial organization. I have enjoyed the journey and am proud to say that we have achieved this goal, as demonstrated in our strong fourth quarter results," said Chad Brown. "I look forward to supporting the transition and will be rooting for John and the team as they continue to develop the spatial biology market."

    "I'd like to extend my sincere thanks to Chad for being my commercial partner for over four great years. Chad led the restructuring of our sales approach, scale-up of our commercial team, and launch of GeoMx DSP, culminating in record-breaking 2021 revenue," stated Brad Gray, president and CEO of NanoString. "John Gerace has spent the last several decades working in some of the most dynamic and competitive markets in life sciences, developing a deep understanding of our customers and winning strategies. His experience in building leading brands across a broad spectrum of life sciences tools and molecular diagnostics will help us bring our products to an expanding global market. In addition, John's experience in business development can help us strengthen our portfolio and ecosystem through partnerships and deal-making."

    Mr. Gerace is a veteran life science executive who brings 35 years of diverse industry experience. Over the prior four years, Mr. Gerace served as president of DiaSorin Molecular, LLC, the global molecular diagnostics business unit of DiaSorin SpA. Prior to DiaSorin, he was president and co-founder of Calabri Biosciences LLC, a consulting firm managing a portfolio of assets related to mobile healthcare diagnostics and monitoring. From April 2015 to December 2016, he served as president and CEO of Freedom Meditech, an early commercial-stage medical device company, which he restructured and sold to Trividia Health, a subsidiary of SinoCare, Inc. From 2007 to 2014, he served in a variety of roles at Applied Biosystems/Life Technologies, including as vice president and general manager of the PCR Systems business unit, and later as head of the Applied Markets business unit, serving the forensic science, animal health, and food safety market segments. Prior to Life Technologies, Mr. Gerace spent 14 years at Beckman Coulter in various sales, marketing, and business development leadership roles. John holds B.S. degrees in Chemistry and Biological Sciences with honors from the University of California at Irvine and a M.B.A. from Pepperdine University. He currently serves on the Board of Directors of the Iacocca Family Foundation, The UC Irvine Foundation, and University Lab Partners.

    "Spatial Biology has emerged as a critical force behind the next decade of life science research and future molecular diagnostics. NanoString is the clear leader in the spatial revolution, providing an entire ecosystem of spatial platforms including instruments, assays, and bioinformatic tools that span the continuum from discovery and translational research today, with the potential to power the next generation of clinical applications," said Mr. Gerace. "NanoString has a seasoned executive team, a long history of technical innovation, and an enviable portfolio of technologies. I look forward to working with Brad and the team to grow the business and create shareholder value."

    About NanoString Technologies, Inc.

    NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company provides three platforms that allow researchers to map the universe of biology. The nCounter® Analysis System, cited in more than 5,200 peer-reviewed publications, offers a way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString's GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections, and has been cited in more than 90 peer-reviewed publications. The CosMx Spatial Molecular Imager, with commercial availability expected in 2022, enables highly sensitive, high-resolution imaging of hundreds to thousands of RNAs or proteins directly from single cells within morphologically intact whole tissue sections. For more information, please visit www.nanostring.com.

    Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding expectations for demand for our products and growth in our business, future revenue growth, the impact of new products and expansion into new markets, the growth trajectory of our nCounter and GeoMx franchises, and the anticipated launch of new products and technology. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; the extent and duration of the impact of the COVID-19 pandemic and adverse conditions in the general domestic and global economic markets; the effects of ongoing litigation; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing and product development; as well as the other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.

    NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220109005033/en/

    Get the next $NSTG alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NSTG

    DatePrice TargetRatingAnalyst
    11/27/2023Overweight → Neutral
    JP Morgan
    11/21/2023Outperform → Neutral
    Robert W. Baird
    7/5/2023$18.00Overweight
    JP Morgan
    2/2/2023$15.00Buy
    UBS
    3/24/2022$50.00Buy
    Canaccord Genuity
    3/2/2022$85.00 → $70.00Overweight
    JP Morgan
    More analyst ratings

    $NSTG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NanoString Announces Completion of Financing to Support Restructuring Process

      $47.5 Million in New Financing Secured from Existing Noteholders, Upsized from Initial $40 million Commitment Supports Mission to Continue Serving Life Sciences Researchers Worldwide NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the Company has entered into a credit agreement with its existing lenders comprised of (a) $12,500,000 in new money term loans which have already been approved for funding pursuant to the February 5 interim order of the U.S. Bankruptcy court approving the credit facility, and (b) an additional $35,000,000 in new money term loans to be funded upon entry of the final

      2/9/24 6:30:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Takes Steps to Restructure Its Business and Protect Its Mission to Map the Universe of Biology

      Initiates Voluntary Chapter 11 Restructuring Proceedings with Additional $40 Million in Financing Secured from Existing Noteholders to Facilitate Process Continuing to Serve Life Sciences Researchers Worldwide NanoString Technologies, Inc. (NASDAQ:NSTG) ("NanoString" or "the Company"), a leading provider of life science tools for discovery and translational research, today announced that steps are being taken to protect its business, customers, employees and its mission to "Map the Universe of Biology." With support from key creditors, NanoString and certain of its subsidiaries have voluntarily initiated a chapter 11 restructuring proceeding in the United States Bankruptcy Court for the

      2/4/24 7:45:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

      Three customers will present inaugural studies powered by the novel CosMx Whole Transcriptome Panel during annual AGBT meeting NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the CosMx™ Human 6K Discovery Panel, the industry's first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. Building on this breakthrough product developed for the CosMx Spatial Molecular Imager (SMI), NanoString and independent researchers will also highlight recently achieved whole transcriptome imag

      2/1/24 6:00:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    SEC Filings

    See more
    • NanoString Technologies Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Financial Statements and Exhibits

      8-K - NanoString Technologies Inc (0001401708) (Filer)

      2/13/24 5:24:14 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - NanoString Technologies Inc (0001401708) (Filer)

      2/8/24 10:45:26 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - NanoString Technologies Inc (0001401708) (Filer)

      2/5/24 6:01:37 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Beechem Joseph M was granted 564 shares, increasing direct ownership by 0.60% to 95,017 units

      4 - NanoString Technologies Inc (0001401708) (Issuer)

      9/5/23 4:38:19 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Gray R Bradley was granted 287 shares, increasing direct ownership by 0.08% to 338,682 units

      4 - NanoString Technologies Inc (0001401708) (Issuer)

      9/5/23 4:36:22 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Garland Jonathan Todd

      4 - NanoString Technologies Inc (0001401708) (Issuer)

      8/28/23 4:26:32 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NanoString Technologies downgraded by JP Morgan

      JP Morgan downgraded NanoString Technologies from Overweight to Neutral

      11/27/23 7:30:05 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies downgraded by Robert W. Baird

      Robert W. Baird downgraded NanoString Technologies from Outperform to Neutral

      11/21/23 7:36:01 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan resumed coverage on NanoString Technologies with a new price target

      JP Morgan resumed coverage of NanoString Technologies with a rating of Overweight and set a new price target of $18.00

      7/5/23 7:22:55 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Leadership Updates

    Live Leadership Updates

    See more
    • NanoString Appoints Todd Garland as Chief Commercial Officer

      NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for discovery and translational research, today announced that Todd Garland has been appointed Chief Commercial Officer, effective August 28, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230826560279/en/NanoString Appoints Todd Garland as Chief Commercial Officer (Photo: Business Wire) Mr. Garland is a senior executive with more than 25 years of experience in healthcare and life sciences technologies that serve customers in the discovery, translational and clinical markets. Most recently Mr. Garland served as Chief Commercial Officer at Cytek B

      8/28/23 5:53:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DermTech Appoints Two New Board Members

      DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company's board of directors, effective July 18,2022. These appointments expand DermTech's board of directors to eight members. "We are excited to welcome Kirk and Mark as new independent directors," commented Matt Posard, DermTech's chairman. "They are both accomplished life science executives, with an established track record in building companies, business development, capital formation and strategic partnerships. Their perspectives in guiding high-growth co

      7/18/22 4:05:00 PM ET
      $DMTK
      $NSTG
      Medical Specialities
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • NanoString Appoints Dr. Teresa Foy to Board of Directors

      Dr. Rob Hershberg steps down from Board after seven years of service NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the appointment of Dr. Teresa (Teri) Foy to the Board of Directors, effective April 18, 2022. "I am honored to welcome Dr. Foy to the team. Teri is a leader in immuno-oncology and cellular therapy, with decades of experience in pharmaceutical research," said president and chief executive officer Brad Gray. "Immunology and oncology are two of the most important applications for spatial biology, and Teri brings a wealth of knowledge in the ways that life science tools are utilized

      4/18/22 4:00:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by NanoString Technologies Inc. (Amendment)

      SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)

      2/14/24 5:16:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by NanoString Technologies Inc. (Amendment)

      SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)

      2/14/24 5:01:20 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by NanoString Technologies Inc.

      SC 13G - NanoString Technologies Inc (0001401708) (Subject)

      2/14/24 4:49:47 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Financials

    Live finance-specific insights

    See more
    • NanoString Technologies Releases Operating Results for Third Quarter of 2023

      Completed Exchange Transaction with Convertible Note Holders Representing 94% of Outstanding Principal – Record Q3 Revenue of $48.1 Million, 63% Year on Year Growth and Above Upper End of Q3 Guidance Range – NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2023. The Company also announced it had reached agreement with holders to exchange approximately $216 million, or 94%, principal amount of its Convertible Notes for new Senior Secured Notes due September 1, 2026 and common stock warrants. "The last few months have been extraordinar

      11/6/23 4:00:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Provides Preliminary Financial and Operational Highlights for Third Quarter of 2023

      - Record Q3 Revenue of Over $48 Million, 63% Year on Year Growth, Above Upper End of Q3 Guidance Range - - Implementing Reorganization of R&D and Manufacturing Operations to Improve Path to Profitability - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the third quarter ended September 30, 2023, as well as a reorganization designed to accelerate the Company's path to profitability. "Our teams delivered strong revenue results for the third quarter, with preliminary results exceeding consensus estimates and the high end of our guidance rang

      10/10/23 6:00:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies Releases Operating Results for Second Quarter of 2023

      – Record Q2 Revenue of $44.2 Million, 37% Year on Year Growth and Above Upper End of Q2 Guidance Range – - Retained More than $35 Million in CosMx Instrument Order Backlog at the End of Q2 - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the second quarter ended June 30, 2023. "Strong growth in our spatial biology business and continued durability in our nCounter business helped us generate record revenue during the second quarter," said Brad Gray, President and CEO of NanoString. "We expect to continue to benefit from substantial CosMx instrument order backlog through

      8/3/23 4:00:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care